Host: Matt Birnholz, MD

Guest: Andrew Chan, MD

Guest: Tobias Derfuss, MD

Evolving treatment options in multiple sclerosis have ushered in a greater focus on providing personalized management to patients with multiple sclerosis. This interview will review the concept of NEDA (No Evidence of Disease Activity), and how its application using new treatment modalities has begun to improve patient outcomes. Join Professor Andrew Chan and Professor Tobias Derfuss as they explore the changing treatment landscape for multiple sclerosis. This is the second of two discussions recorded at McCann Complete Medical’s special meeting on multiple sclerosis held in Baveno, Italy. Click here to view the first discussion titled Innovations in MS: Mechanisms of Disease Progression and Immune Reconstitution. Disclaimer: Some products discussed in this activity have not received regulatory approval by the US FDA for the treatment of patients with Multiple Sclerosis. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”